Ontology highlight
ABSTRACT:
SUBMITTER: Cabanillas ME
PROVIDER: S-EPMC7341904 | biostudies-literature | 2019 Dec
REPOSITORIES: biostudies-literature
Endocrine reviews 20191201 6
The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade, with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a number of other commercially available drugs that have been studied for this indication. Although most of the US Food and Drug Administration (FDA)-approved drugs are antiangiogenic multikinase inhibitors-vandetanib, cabozantinib, sorafenib, lenvatinib-there are two FDA indications that are mutation specific-dabrafenib/t ...[more]